



(51) International Patent Classification:

A61K 31/164 (2006.01) A61K 45/06 (2006.01)
A61K 31/56 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2010/054866

(22) International Filing Date:

27 October 2010 (27.10.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/256,160	29 October 2009 (29.10.2009)	US
61/293,903	11 January 2010 (11.01.2010)	US
61/355,834	17 June 2010 (17.06.2010)	US
61/355,888	17 June 2010 (17.06.2010)	US
61/369,929	2 August 2010 (02.08.2010)	US
61/383,933	17 September 2010 (17.09.2010)	US
61/389,969	5 October 2010 (05.10.2010)	US

(71) Applicant (for all designated States except US): **AVENTIS PHARMA S.A.** [FR/FR]; 20 avenue Raymond Aron, F-92160 Antony (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GUPTA, Sunil** [US/US]; c/o Sanofi-Aventis US, Inc., 1041 Routes 202-206 Mail Code: D-303A, Bridgewater, New Jersey 08807 (US).

(74) Agent: **GASLONDE, Aude**; c/o Sanofi-Aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NOVEL ANTITUMORAL USE OF CABAZITAXEL



(57) Abstract: The invention relates to a compound of Formula (I): which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.